PRDX5 and non-small cell lung carcinoma: Furthermore, cisplatin down-regulated the survival rate of the NSCLC cells in the PRDX5 shRNA group, Nrf2 shRNA group, and PRDX5+Nrf2 shRNA group by 0.245, 0.273 and 0.295.